Zentalis Pharmaceuticals Inc (ZNTL) Stock Analysis

Verdict: WATCH (do not buy)

ZNTL is a high-alpha clinical play where positive trial beats are currently overshadowed by a lethal $125M burn vs $36M cash disparity.

Investment score: 48/100

Analysis as of

Is Zentalis Pharmaceuticals Inc stock worth reviewing? AI model thesis

The model avoids a 'Buy' rating due to an immediate liquidity crisis despite strong technical momentum. The company has a PB of 0.45x and impressive earnings beats, but until the funding gap is addressed, any rally is likely to be capped by an equity offering.

7-factor investment score

Zentalis Pharmaceuticals Inc opportunities and risks

What speaks for ZNTL

What speaks against ZNTL

Peers and competitors

Trailing-twelve-month ratios
TickerP/EP/SEV/EBITDAGross marginNet marginFCF yield
ZNTLn/a0.0xn/a0.0%0.0%-45.1%
TENXn/a0.0xn/a0.0%0.0%-19.6%
IMRXn/a0.0x737.8x0.0%0.0%-30.1%
LYELn/a9250.8xn/a-7422.6%-794858.1%-46.9%
ARMPn/a100.7xn/a72.2%-9554.2%-8.2%
Peer mediann/a50.3xn/a0.0%-4777.1%-24.9%

Frequently asked questions about Zentalis Pharmaceuticals Inc (ZNTL)

Is ZNTL stock a good investment?

The cached TradeMates AI model rates Zentalis Pharmaceuticals Inc as WATCH (do not buy) with an investment score of 48/100. The model avoids a 'Buy' rating due to an immediate liquidity crisis despite strong technical momentum. The company has a PB of 0.45x and impressive earnings beats, but until the funding gap is addressed, any rally is likely to be capped by an equity offering. This is algorithmic model output, not personal investment advice.

Is ZNTL stock a buy?

The TradeMates model verdict for ZNTL is WATCH (do not buy) with an investment score of 48/100. Treat this as a model signal to review, not a personal buy recommendation.